Edition:
United States

pSivida Corp (PSDV.OQ)

PSDV.OQ on NASDAQ Stock Exchange Global Market

1.18USD
3:59pm EST
Change (% chg)

$-0.05 (-4.07%)
Prev Close
$1.23
Open
$1.23
Day's High
$1.23
Day's Low
$1.17
Volume
62,570
Avg. Vol
66,759
52-wk High
$2.45
52-wk Low
$1.04

Chart for

About

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that... (more)

Overall

Beta: 1.31
Market Cap(Mil.): $55.67
Shares Outstanding(Mil.): 45.26
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-pSivida reports Q1 loss per share of $0.15

* Q1 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Nov 07 2017

BRIEF-Nicox and pSivida enter strategic collaboration agreement

* REG-NICOX AND PSIVIDA ENTER STRATEGIC COLLABORATION AGREEMENT TO DEVELOP SUSTAINED RELEASE DRUG TO LOWER INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA

Oct 10 2017

BRIEF-Nicox and pSivida enter collaboration agreement to develop sustained release drug for glaucoma patients​

* Nicox-Co and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma​

Oct 10 2017

BRIEF-pSivida partners with global pharmaceuticals company to develop sustained release formulations of glaucoma drugs

* pSivida partners with global pharmaceuticals company to develop sustained release formulations of glaucoma drugs

Sep 26 2017

BRIEF-pSivida Corp reports Q4 loss per share $0.16

* pSivida Corp achieves significant milestones throughout fy 2017; reports fourth quarter and fiscal 2017 results

Sep 11 2017

BRIEF-pSivida- in connection with new collaboration agreement, Alimera forgave $10 mln of co's share of losses associated with commercialization of ILUVIEN

* pSivida - in connection with new collaboration agreement, alimera forgave $10 million of co's share of losses associated with commercialization of ILUVIEN

Jul 10 2017

BRIEF-Psivida out-licenses EMEA rights for Durasert three-year treatment for posterior segment Uveitis

* Psivida out-licenses emea rights for durasert™ three-year treatment for posterior segment uveitis while retaining u.s. Commercial rights; amended global collaboration agreement with alimera for iluvien® improves psivida’s revenue generation

Jul 10 2017

BRIEF-Psivida submits marketing authorization application for approval of Durasert in EU

* Psivida submits marketing authorization application (maa) for approval of durasert™ three-year treatment for posterior segment uveitis in European Union

Jun 22 2017

BRIEF-Psivida's Durasert successfully achieves primary efficacy endpoint in second phase 3 study

* Psivida's Durasert three-year treatment for posterior segment uveitis successfully achieves primary efficacy endpoint in second phase 3 study

Jun 13 2017

Earnings vs. Estimates